Drug news
NICE reverses decision to recommend Imbruvica
The National Institute for Health and Care Excellence (NICE) in a final appraisal has changed its earlier negative recommendation and now recommends Imbruvica (ibrutinib) from Janssen Biotech to treat patients with relapsed or refractory Mantle Cell Lymphoma who have has just one prior therapy. The decision followed offer of a confidential discount.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins